Amlodipine versus angiotensin II receptor blocker; control of blood pressure evaluation trial in diabetics (ADVANCED-J)

• Main Authors: Ikeda Shunya, Kishimoto Junji, Hayashi Dobun, Kitagawa Akira, Miyauchi Katsumi, Tanaka Yasushi, Daida Hiroyuki, Kawamori Ryuzo, Imai Yutaka, Yamazaki Tsutomu
• Format: Article
• Language: English
• Published: BMC 2006-10-01
• Series: BMC Cardiovascular Disorders
• Online Access: http://www.biomedcentral.com/1471-2261/6/39

<p>Abstract</p> <p>Background</p> <p>The coexistence of type 2 diabetes mellitus and hypertension increases the risk of cardiovascular diseases. The U.K. Prospective Diabetes Study has shown that blood pressure control as well as blood glucose control is efficient for prevention of complications in hypertensive patients with diabetes mellitus. However, some reports have shown that it is difficult to control the blood pressure and the concomitant use of a plurality of drugs is needed in hypertensive patients with diabetes mellitus. In recent years renin-angiotensin system depressants are increasingly used for the blood pressure control in diabetic patients. Particularly in Japan, angiotensin II (A II) antagonists are increasingly used. However, there is no definite evidence of the point of which is efficient for the control, the increase in dose of A II antagonist or the concomitant use of another drug, in hypertensive patients whose blood pressure levels are inadequately controlled with A II antagonist.</p> <p>Methods/Design</p> <p>Hypertensive patients of age 20 years or over with type 2 diabetes mellitus who have been treated by the single use of AII antagonist at usual doses for at least 8 weeks or patients who have been treated by the concomitant use of AII antagonist and an antihypertensive drug other than calcium channel blockers and ACE inhibitors at usual doses for at least 8 weeks are included.</p> <p>Discussion</p> <p>We designed a multi-center, prospective, randomized, open label, blinded-endpoint trial, <it>ADVANCED-J</it>, to compare the increases in dose of A II antagonist and the concomitant use of a Ca-channel blocker (amlodipine) and A II antagonist in hypertensive patients with diabetes mellitus, whose blood pressure levels were inadequately controlled with A II antagonist. This study is different from the usual previous studies in that home blood pressures are assessed as indicators of evaluation of blood pressure. The <it>ADVANCED-J </it>study may have much influence on selection of antihypertensive drugs for treatment in hypertensive patients with diabetes mellitus. It is expected to give an important hint for considering the validity of selection of antihypertensive drugs from the aspects not only of the antihypertensive effect but medical cost-effectiveness.</p>